Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia - Wikidata - wikimedia - TriplyDB

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q36339717

about

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia Declining childhood and adolescent cancer mortality Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products The myth of the second remission of acute leukemia in the adult.Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia A 50-year journey to cure childhood acute lymphoblastic leukemia Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Current and future management of Ph/BCR-ABL positive ALL.Novel antibody therapy in acute lymphoblastic leukemia.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.Current status of antibody therapy in ALL.Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.Novel approaches to pediatric leukemia treatment.Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.Personalized medicine in adult acute lymphoblastic leukemia.Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia.Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.Rituximab in the management of acute lymphoblastic leukemia.A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model.Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database.

P2860

Q26764903-0F75843F-6E03-47A3-8D0D-98C890BBDBC6 Q26783425-099C7DE4-0B83-4C33-AA01-EB1647D745EC Q27006773-3A44D68D-5D24-489B-BF63-4D37B4CF2AF3 Q34060045-5FC7791F-18EB-4D76-BEDD-EB27D4A47F02 Q35051430-CD7F1E13-8842-42EC-AC87-450BA34F2404 Q36131489-E1FF1A1F-1087-4E1F-9183-59E7C6F46ED1 Q36273796-84103A37-1B1C-4CD6-92A4-45ADB042042D Q36619678-E849D5D0-E38E-4826-8F02-3DBF9AB16F92 Q36619703-40CDBD4D-4D2F-42C9-BE84-014B31B0A552 Q36781942-E4521525-A3D1-4890-9BCA-D1C2BCBDB972 Q37166753-83281F38-D59D-4A9E-90E4-5D97DBEBBE12 Q37282218-0A37714C-8B8A-4721-8554-6ADA779B5F1A Q37517482-E8228A14-CFD0-401C-9520-87480EECC379 Q38094099-DA72C8A6-18B7-4786-933C-0AF224366F8E Q38194585-9FF4A229-CDF0-4E19-A6D7-E92734ECDD3C Q38195539-5BB3A8EF-2872-4D97-A5BB-986590FF8BAF Q38224988-8174427B-D333-4BD3-8FB1-121A5333EC6B Q38266338-DC5FF11B-D8B1-46B0-8C2C-031F2493729D Q38282458-29FF8A42-EF20-47CF-B743-A04EE2DAB7EF Q38312596-7D1447B2-60EA-47BB-9D6B-EF44716854E9 Q38434000-53E20669-0236-4E63-9271-A201EA1B9F73 Q38452047-B8C667A9-8A6B-4D50-AEB3-22A1FB8753AC Q38500371-C4AA79EA-1735-4D61-9E52-243E45D800D8 Q38701163-793D8474-52D8-4B85-9CED-7CB2CD53C7FA Q40312849-470A2681-2A21-47D0-8356-4271467E8DA8 Q42384621-47CE0D55-3B35-40F0-9667-CCF8A9C06D0B Q42556477-F867A887-4634-4BD6-9A59-42525C32477D Q45347246-CCE7A95B-9230-4D81-B05F-E577A5F53BDC Q46385489-57504DFE-1E41-475F-98E4-8A267E91F8B0 Q47196522-E077CC28-C886-4261-8913-C9B576A536CA Q47357871-EDE343D2-457E-4453-A91F-BEA299E0AEF8 Q47774455-E6809D69-7016-4ED0-A8D8-687F4FF0CD93 Q48154770-359F7DDB-C6AD-4049-9BD2-B18A5442743C

P2860

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q36339717

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@ast

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@en

type

label

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@ast

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@en

prefLabel

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@ast

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@en

P1433

Q36339717-FFC85EF3-2F09-4C05-835B-9F550CFACAFC

P1476

Q36339717-8C275A74-C09E-4C0A-85EA-8DA59BB0038C

P2093

Q36339717-0B2F1F4B-9B2A-4B56-9B69-8DE37B0468C1

Q36339717-98E4A3DA-E75B-4331-9A58-9F253CA462E6

P2860

Q36339717-04D2E89E-F2ED-41DE-A227-E934EBDC1F62

Q36339717-0D810564-9E01-47DE-82EB-082A943407C2

Q36339717-1144354F-3899-440A-981E-FA9ADAA2DEF4

Q36339717-148123AD-7C6B-4FCC-8BDC-BA5A5C569F23

Q36339717-19587520-08D1-4372-828E-D2C2151E1CF1

Q36339717-1F5AE416-4B31-4532-9F4C-EFF2DF51230A

Q36339717-20107CE2-3640-4EB3-BA08-0917820922CA

Q36339717-20EE19A1-02EC-44AA-B972-1B2B1046F7A1

Q36339717-23A50B06-0026-4D90-A09F-B4FA7059248A

Q36339717-2AA9EBA6-1AC2-4362-B0BB-60F9508B1889

P304

Q36339717-22B5BA98-9E62-4A10-A42A-DC274EAD2B63

P31

Q36339717-36329F9B-EEE9-40AD-881A-8BEF201FA144

P356

Q36339717-2FE8E1D2-1F22-4339-BFEF-003089C9D59F

P407

Q36339717-25CF5DF9-949C-4E19-9189-8E0790F6D04F

P433

Q36339717-265C005A-3FD3-4B6B-A674-251EFE776916

P478

Q36339717-8D8D2541-D28F-4066-9BA8-DB71E87831BE

P50

Q36339717-C8FFAF63-019E-4A65-8C3B-CA5C548E0485

Q36339717-FD5B33AB-9EE2-4400-BA44-8AC21BD7D124

P577

Q36339717-0BE39CB5-733D-415C-9A4D-16A7ACE4DB84

P698

Q36339717-FEE48DDA-E142-4712-B457-6D1D9B7A3D1E

P921

Q36339717-291E2105-0398-461C-B0D7-D025564C3EF2

Q36339717-48FF3B35-970A-4DED-B958-53793D31485A

P932

Q36339717-15CE6A02-B580-4F26-A26D-0A3DB5804BBF

P356

JCO.2012.41.6768

P1433

Journal of Clinical Oncology

P1476

Monoclonal antibody-based ther ...... f acute lymphoblastic leukemia

@en

P2093

Alan S Wayne

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

P304

3876-3883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.41.6768

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

P577

2012-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22891271

http://www.w3.org/2001/XMLSchema#string

P921

P932

3478578

http://www.w3.org/2001/XMLSchema#string